146 related articles for article (PubMed ID: 9823973)
21. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
Rosenzweig KE; Mychalczak B; Fuks Z; Hanley J; Burman C; Ling CC; Armstrong J; Ginsberg R; Kris MG; Raben A; Leibel S
Cancer J; 2000; 6(2):82-7. PubMed ID: 11069224
[TBL] [Abstract][Full Text] [Related]
22. Comparison of two dimensional and three dimensional radiotherapy treatment planning in locally advanced non-small cell lung cancer treated with continuous hyperfractionated accelerated radiotherapy weekend less.
Wilson EM; Joy Williams F; Lyn BE; Aird EG
Radiother Oncol; 2005 Mar; 74(3):307-14. PubMed ID: 15763312
[TBL] [Abstract][Full Text] [Related]
23. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).
van Diessen J; De Ruysscher D; Sonke JJ; Damen E; Sikorska K; Reymen B; van Elmpt W; Westman G; Fredberg Persson G; Dieleman E; Bjorkestrand H; Faivre-Finn C; Belderbos J
Radiother Oncol; 2019 Feb; 131():166-173. PubMed ID: 30327236
[TBL] [Abstract][Full Text] [Related]
24. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
26. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
[TBL] [Abstract][Full Text] [Related]
27. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer.
De Ruysscher D; Wanders R; van Haren E; Hochstenbag M; Geraedts W; Pitz C; Simons J; Boersma L; Verschueren T; Minken A; Bentzen SM; Lambin P
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):132-8. PubMed ID: 18037581
[TBL] [Abstract][Full Text] [Related]
28. An accelerated radiotherapy scheme using a concomitant boost technique for the treatment of unresectable stage III non-small cell lung cancer.
Izmirli M; Yaman F; Buyukpolat MY; Yoney A; Unsal M
Jpn J Clin Oncol; 2005 May; 35(5):239-44. PubMed ID: 15886271
[TBL] [Abstract][Full Text] [Related]
29. Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: a dose-escalation planning study.
Lievens Y; Nulens A; Gaber MA; Defraene G; De Wever W; Stroobants S; Van den Heuvel F;
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):306-13. PubMed ID: 20888706
[TBL] [Abstract][Full Text] [Related]
30. Radiation pneumonitis following treatment of non-small-cell lung cancer with continuous hyperfractionated accelerated radiotherapy (CHART).
Jenkins P; D'Amico K; Benstead K; Elyan S
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):360-6. PubMed ID: 12738310
[TBL] [Abstract][Full Text] [Related]
31. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter.
Pradier O; Lederer K; Hille A; Weiss E; Christiansen H; Schmidberger H; Hess CF
J Cancer Res Clin Oncol; 2005 Apr; 131(4):261-9. PubMed ID: 15616830
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy followed by late-course accelerated hyperfractionated radiation therapy for locally advanced non-small-cell lung cancer: long-term results of a phase I/II clinical trial.
Chen M; Chen YY; Bao Y; Xian CG; Liu GZ; Zhang L; Xu GC; Deng XW; Lu TX; Qian JY; Cui NJ
Clin Lung Cancer; 2005 Mar; 6(5):304-9. PubMed ID: 15845182
[TBL] [Abstract][Full Text] [Related]
33. No thoracic radiation myelitis after spinal cord dose > or = 50.4 Gy using 1.2. Gy b.i.d. fractionation in patients with Stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy.
Jeremic B; Shibamoto Y; Milicic B; Dagovic A; Aleksandrovic J; Nikolic N; Igrutinovic I
Lung Cancer; 2002 Mar; 35(3):287-92. PubMed ID: 11844603
[TBL] [Abstract][Full Text] [Related]
34. Validation of active breathing control in patients with non-small-cell lung cancer to be treated with CHARTWEL.
Wilson EM; Williams FJ; Lyn BE; Wong JW; Aird EG
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):864-74. PubMed ID: 14529794
[TBL] [Abstract][Full Text] [Related]
35. Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres.
Sanganalmath P; Lester JE; Bradshaw AG; Das T; Esler C; Roy AEF; Toy E; Lester JF; Button M; Wilson P; Comins C; Atherton P; Pickles R; Foweraker K; Walker GA; Keni M; Hatton MQ
Clin Oncol (R Coll Radiol); 2018 Mar; 30(3):144-150. PubMed ID: 29336865
[TBL] [Abstract][Full Text] [Related]
36. A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer.
Cagney DN; Thirion PG; Dunne MT; Fleming C; Fitzpatrick D; O'Shea CM; Finn MA; O'Sullivan S; Booth C; Collins CD; Buckney SJ; Shannon A; Armstrong JG
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):30-38. PubMed ID: 29097074
[TBL] [Abstract][Full Text] [Related]
37. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
Jeremić B; Milicić B
Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
[TBL] [Abstract][Full Text] [Related]
38. DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
Wurstbauer K; Zehentmayr F; Deutschmann H; Dagn K; Exeli AK; Kopp P; Porsch P; Maurer B; Studnicka M; Sedlmayer F
Strahlenther Onkol; 2017 Apr; 193(4):315-323. PubMed ID: 28116446
[TBL] [Abstract][Full Text] [Related]
39. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
[TBL] [Abstract][Full Text] [Related]
40. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
